Concordia Healthcare Corp. is a specialty pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its segments are Concordia North America, Concordia International, Orphan Drugs and Corporate cost centre. Its Concordia North America segment includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer. The Concordia International segment includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines. The Orphan Drugs segment includes Photofrin, which is for the treatment of certain forms of rare cancer. The Corporate cost centre segment includes centralized costs incurred by the Company.